These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 6382892

  • 21. A study of serum free C-peptide responses to oral glucose load in diabetic patients: with special reference to types of diabetes and methods of treatment.
    Hsieh SD, Akanuma Y, Takaku F.
    Tohoku J Exp Med; 1984 Mar; 142(3):249-60. PubMed ID: 6374968
    [Abstract] [Full Text] [Related]

  • 22. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.
    Hosker JP, Rudenski AS, Burnett MA, Matthews DR, Turner RC.
    Metabolism; 1989 Aug; 38(8):767-72. PubMed ID: 2668699
    [Abstract] [Full Text] [Related]

  • 23. Effect of strict blood glucose control on residual B-cell function in insulin-dependent diabetics.
    Madsbad S, Krarup T, Reguer L, Faber OK, Binder C.
    Diabetologia; 1981 May; 20(5):530-4. PubMed ID: 7026327
    [Abstract] [Full Text] [Related]

  • 24. Residual B cell function in patients with long-standing NIDDM and its relation to metabolic control and diabetic complications.
    Iwase M, Kikuchi M, Nunoi K, Maki Y, Wakisaka M, Wada M, Fujishima M.
    Endocrinol Jpn; 1988 Dec; 35(6):803-8. PubMed ID: 3074917
    [Abstract] [Full Text] [Related]

  • 25. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH.
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [Abstract] [Full Text] [Related]

  • 26. beta-cell function in children with diabetes.
    Ludvigsson J, Heding LG.
    Diabetes; 1978 Sep; 27 Suppl 1():230-4. PubMed ID: 344114
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Beta cell function in long term NIDDM (type 2) patients and its relation to treatment.
    Snehalatha C, Ramachandran A, Mohan V, Timothy H, Viswanathan M.
    Horm Metab Res; 1986 Jun; 18(6):391-4. PubMed ID: 3525362
    [Abstract] [Full Text] [Related]

  • 29. Fasting plus prandial insulin supplements improve insulin secretory ability in NIDDM subjects.
    Kawamori R, Bando K, Yamasaki Y, Kubota M, Watarai T, Iwama N, Shichiri M, Kamada T.
    Diabetes Care; 1989 Jun; 12(10):680-5. PubMed ID: 2515048
    [Abstract] [Full Text] [Related]

  • 30. Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes.
    Albareda M, Rigla M, Rodríguez-Espinosa J, Caballero A, Chico A, Cabezas R, Carreras G, Pérez A.
    Diabetes Res Clin Pract; 2005 Jun; 68(3):202-6. PubMed ID: 15936461
    [Abstract] [Full Text] [Related]

  • 31. Effects of the combination of insulin and gliclazide compared with insulin alone in type 2 diabetic patients with secondary failure to oral hypoglycemic agents.
    Aschner P, Kattah W.
    Diabetes Res Clin Pract; 1992 Oct; 18(1):23-30. PubMed ID: 1446575
    [Abstract] [Full Text] [Related]

  • 32. betacell function during insulin or chlorpropamide treatment of maturity-onset diabetes mellitus.
    Turner RC, Holman RR.
    Diabetes; 1978 Oct; 27 Suppl 1():241-6. PubMed ID: 344115
    [Abstract] [Full Text] [Related]

  • 33. Plasma C-peptide levels identify insulin-treated diabetic patients suitable for oral hypoglycaemic therapy.
    Grant PJ, Barlow E, Miles DW.
    Diabet Med; 1984 Nov; 1(4):284-6. PubMed ID: 6242818
    [Abstract] [Full Text] [Related]

  • 34. Variation of endogenous insulin secretion in association with treatment status: assessment by serum C-peptide and modified urinary C-peptide.
    Aoki Y.
    Diabetes Res Clin Pract; 1991 Dec; 14(3):165-73. PubMed ID: 1778109
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
    Rosak C, Hofmann U, Paulwitz O.
    Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
    [Abstract] [Full Text] [Related]

  • 40. Glucagon-stimulated insulin secretion in patients with type 2 diabetes mellitus: support for the concept of glucose toxicity.
    Wolffenbuttel BH, Menheere PP, Nijst L, Rondas-Colbers GJ, Sels JP, Nieuwenhuijzen Kruseman AC.
    Neth J Med; 1992 Jun; 40(5-6):277-82. PubMed ID: 1436266
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.